our science

The ACT Solution

Excelimmune is developing a new wave of Antibody Combination Therapeutics (ACT), which will become the new standard of care for monotherapy-resistant infectious and oncological diseases. The company's vision is to develop and produce multi-antibody therapeutics that mimic the effectiveness and resistance to escape mutants typically exhibited by the adaptive humoral immune response of a healthy, human being. Excelimmune is using its expression platform to create a pipeline of combination antibody products composed of five or more high-affinity, high-specificity antibodies, each with a specific functional activity.

Excelimmune's ACT Technology Suite »